Join Growin Stock Community!

華安6657.TW Overview

TW StockBiotech. & Medical
(No presentation for 6657)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

華安（6657）Overall Performance

華安（6657）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

華安（6657） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

華安（6657）Key Information

華安（6657）Profile

Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase II clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel disease; ENERGI-F708 for asthma treatment; ENERGI-F705 for Parkinson's disease control; ENERGI-F707 for the treatment of mitochondria deficiency; ENERGI-F706 to treat cachexia; ENERGI-F709, a vaccine adjuvant; and ENERGI-F710 for blood phosphate control. The company also offers scientific products, which include western blot, cell culture supplement, protein isolation, protein quantification, dyes, and buffer solutions. Energenesis Biomedical CO.,LTD. was founded in 2012 and is based in Taipei, Taiwan.

華安（6657）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

No related data records

  • When is 6657's latest earnings report released?

    The most recent financial report for 華安 (6657) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6657's short-term business performance and financial health. For the latest updates on 6657's earnings releases, visit this page regularly.

  • What is the operating profit of 6657?

    According to the latest financial report, 華安 (6657) reported an Operating Profit of -52.64M with an Operating Margin of -3,327.62% this period, representing a growth of 42.45% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6657's revenue growth?

    In the latest financial report, 華安 (6657) announced revenue of 1.58M, with a Year-Over-Year growth rate of -25.2%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6657 have?

    At the end of the period, 華安 (6657) held Total Cash and Cash Equivalents of 628.14M, accounting for 0.61 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6657 go with three margins increasing?

    In the latest report, 華安 (6657) did not achieve the “three margins increasing” benchmark, with a gross margin of 78.26%%, operating margin of -3,327.62%%, and net margin of -3,097.85%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6657's profit trajectory and future growth potential.

  • Is 6657's EPS continuing to grow?

    According to the past four quarterly reports, 華安 (6657)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.55. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6657?

    華安 (6657)'s Free Cash Flow (FCF) for the period is -4.85M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 22.57% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

default symbol

6657

華安

48.00D

-5.42%

(-0.05)